Divide and conquer:identifying acute respiratory distress syndrome subphenotypes by Shankar-Hari, Manu & McAuley, Daniel F
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1136/thoraxjnl-2017-210422
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Shankar-Hari, M., & McAuley, D. F. (2017). Divide and conquer: identifying acute respiratory distress syndrome
subphenotypes. Thorax, 72(10), 867-869. https://doi.org/10.1136/thoraxjnl-2017-210422
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Divide and conquer: Identifying Acute Respiratory Distress Syndrome sub-phenotypes 
Manu Shankar-Hari1,2 and Daniel F. McAuley3,4#  
1Department of Critical Care Medicine, Guy’s and St Thomas’ NHS Foundation Trust, Westminster 
Bridge Rd, London SE17EH, United Kingdom; 2Division of Infection and Immunity, King’s College 
London, United Kingdom; 3Centre for Experimental Medicine, Wellcome-Wolfson Institute for 
Experimental Medicine, Queen's University of Belfast, Belfast, Northern Ireland; 4Regional Intensive 
Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland 
 
Manu Shankar-Hari1,2 M.Sc., Ph.D. 
email: manu.shankar-hari@kcl.ac.uk 
Twitter: @msh_manu 
 
#Corresponding author 
Professor Daniel F McAuley 
3Centre for Experimental Medicine, Wellcome-Wolfson Institute for Experimental Medicine, Queen's 
University of Belfast, Belfast, Northern Ireland; 4Regional Intensive Care Unit, Royal Victoria Hospital, 
Grosvenor Road, Belfast, Northern Ireland 
email: d.f.mcauley@qub.ac.uk 
Tel: 0044 28 90635794 
Word count = 1025 (excluding Table) 
References = 13 
Figures and tables = 1 table 
Key words: ARDS, Humans, Phenotypes, Enrichment; Stratified Medicine 
 
 
The acute respiratory distress syndrome (ARDS) definition identifies patients with acute onset 
hypoxaemia and respiratory failure, who have bilateral opacities on chest radiograph that are not fully 
explained by cardiac failure or fluid overload1. ARDS is a common illness that accounts for 
approximately 10% of critical care admissions and 20% of patients requiring mechanical ventilation2. 
The hospital mortality in patients with ARDS remains high, increasing from approximately 35% for 
those with mild disease to 46% for those with severe ARDS2. This high mortality has remained 
relatively unchanged in the last 20 years3. To date, despite decades of research, there is no 
pharmacological treatment that can modify the underlying biological mechanisms implicated in ARDS 
and improve patient outcomes4. Within ARDS populations there is substantial biological and outcome 
heterogeneity, with observed differences in dominant pathogenic mechanisms, treatment responses 
and outcomes5-7. Identifying ARDS sub-phenotypes based on biological characteristics 
mechanistically linked to specific therapies irrespective of the baseline risk of outcome, is the 
conceptual definition of predictive enrichment7 8. The identification of such ARDS sub-phenotypes will 
enable improved trial design in ARDS by selecting patients based on responder characteristics to 
therapeutic interventions, hopefully resulting in improved outcomes6.  
In this issue of Thorax, Bos et al report an excellent cohort study in 700 ARDS patients, 
testing the hypothesis that ARDS sub-groups exist due to difference in biological characteristics9. In 
this retrospective analysis of a prospectively collected cohort, 20 biomarkers were selected to 
represent inflammation, coagulation and endothelial activation, as hallmarks of ARDS biology6. The 
dataset was divided into a training cohort (n=454 patients) and validation cohort (n=246 patients), 
based on the study recruitment period. Cluster analysis was used to identify homogenous ARDS sub-
phenotypes in the training cohort10. The most predictive biomarkers were then confirmed in the 
validation cohort. These biological clusters were then linked to clinical and outcome characteristics of 
ARDS patients to derive clinical sub-phenotypes, namely reactive and uninflamed. These two clinical 
ARDS sub-phenotypes differed in terms of illness severity and critical care mortality, with the reactive 
group having a greater risk of death.  
A key question for the reader is whether these associations are spurious or indirect or 
causal?11 Cluster analysis methods generate different results dependent on the variables chosen for 
identifying similarities between patients and the method of clustering10. Bos et al chose biomarker 
characteristics as the variables on which the groups should be similar, and used Ward’s method of 
agglomerative hierarchical clustering to identify two potentially generalizable ARDS clusters. 
Hierarchical clustering is a commonly used iterative method to identify homogenous groups or 
clusters based on specific characteristics. In the paper by Bos et al, the goal was to identify ARDS 
patients with similar biomarker profiles, from a heterogeneous ARDS cohort. The basic algorithm 
starts with assigning each ARDS patient a ‘value’ based on their individual biomarker profile. Then 
patients with similar ‘values’ are grouped together to form clusters. The underlying principle is that 
ARDS patients within each cluster will have similar biomarker profiles and that between clusters 
biomarker profiles will be different. Depending on the parameters specified, the same dataset can 
result in potentially different results with different clustering algorithms and there are no universally 
agreed optimal rule(s) for clustering10. Another potential limitation is that only patients with data on all 
chosen biomarkers were included and missing data in clinical variables were imputed, which has the 
potential for selection and information bias. The blood sampling window for biomarker measurement 
in this cohort was wide and drawn either on the day of ARDS diagnosis or the day before or the day 
after, challenging the time-based arguments for a causal relationship. Despite these challenges, Bos 
et al provide important data with strong associations that are consistent with our current knowledge, 
have biological plausibility and external validity. 
 Calfee and colleagues have led the field in defining ARDS sub-phenotypes. Using latent class 
analysis (LCA) of clinical and biomarker data from patients enrolled in ARDS randomised controlled 
trials, Calfee et al have originally identified two ARDS sub-phenotypes12 13. The reactive sub-
phenotype identified in this study shares many of the features of the hyperinflammatory ARDS sub-
phenotype reported previously12 13, although the proportion of patients in the reactive group is much 
higher than the hyperinflammatory sub-phenotype. This suggests that the hyperinflammatory and 
reactive groups may represent a similar sub-phenotype, although this is unproven. The findings from 
this study are significant in that they have identified comparable sub-phenotypes in an observational 
cohort of patients with ARDS using a different analytic approach. Whilst Calfee et al identified these 
ARDS sub phenotypes using clinical and biomarker data, Bos et al identified them purely on 
biomarker data. It would be important to test whether similar sub-phenotypes emerge after 
harmonising these different study datasets and performing both cluster and latent class analyses. 
Table 1 provides a comparative summary of these three studies. 
 
 
Table 1: Summary of studies that report ARDS sub-phenotypes 
Parameter Bos et al9 Calfee C et al13 Famous et al12 
Sample size 700 1022 1000 
Recruitment 
period 
2011 – 2013 1996 – 2002 2000 - 2005 
Study design Observational cohort RCT analysed as cohort RCT analysed as cohort 
ARDS P/F criteria <=300 <300 <300 
Blood sampling Around ARDS diagnosis At baseline At baseline 
Biomarkers used 
for deriving sub-
phenotypes 
Lung epithelial: none 
Endothelial: E-selectin; P-
selectin; ANG1/2 
Coagulation: Antithrombin; D-
Dimer; tPA; PAI-1; 
Inflammation: Fractalkine; 
GM-CSF; ICAM-1; IFN-γ; IL-1β; 
IL-6; IL-8; IL-10; IL-13; TNF-α; 
MMP-8; TIMP-1; 
Lung epithelial: SP-D 
Endothelial: ICAM-1; vWF 
 
Coagulation: Protein C; PAI-1 
 
Inflammation: sTNFR-1; IL-6; 
IL-8 
 
Lung epithelial: SP-D 
Endothelial: ICAM-1; vWF 
 
Coagulation: Protein C; PAI-1 
 
Inflammation: sTNFR-1; IL-6; 
IL-8 
 
Clinical variables 
used for deriving 
sub-phenotypes 
None Age, gender, ethnicity, BMI, 
Respiratory#; Cardiovascular*; 
Creatinine; Urine output; 
Bilirubin; Temperature; 
Haematocrit; WBC count; 
Sodium; glucose; Albumin; 
Platelets; bicarbonate; 
Aetiology of ARDS^ 
Age, gender, ethnicity, BMI, 
Respiratory#; Cardiovascular*; 
Creatinine; Urine output; 
Bilirubin; Temperature; 
Haematocrit; WBC count; 
Sodium; glucose; Albumin; 
Platelets; bicarbonate; 
Aetiology of ARDS^ 
Analytical 
approach to derive 
ARDS subsets 
Cluster analyses based only on 
biomarker data 
Latent class analyses based 
grouping based on clinical and 
biomarker data 
Latent class analyses based 
grouping based on clinical and 
biomarker data 
ARDS subset 
(prevalence %) 
Reactive phenotype (58.0%) 
Vs 
Uninflamed (42.0%) 
Hyper-Inflammatory (29.4%) 
Vs 
Phenotype 1 (70.6%) 
Hyper-Inflammatory (27.3%) 
Vs 
Phenotype 1 (72.7%) 
Mortality (%) by 
ARDS subset 
Reactive phenotype = 36.8% 
Vs 
Uninflamed = 14.9% 
Hyper-Inflammatory = 47.3% 
Vs 
Phenotype 1 = 19.4% 
Hyper-Inflammatory = 45.0% 
Vs 
Phenotype 1 = 22.0% 
Discriminant 
markers between 
phenotypes 
IL-6; IFN-gamma; ANG1/2; PAI-
1 
IL-6; sTNFR1; Vasopressor 
use; IL-8; HCO3 
IL-8; sTNFR1; Vasopressor 
use; HCO3; minute ventilation 
 
Legend to Table-1: 
Table-1 shows the summary of three recent studies that report ARDS sub-phenotypes. The Respiratory system variables# 
included minute ventilation, mean airway pressure, plateau pressure, respiratory rate, tidal volume, positive end-expiratory 
pressure; partial pressure of carbondioxide (PaCO2) and PaO2/FiO2 ratio. The Cardiovascular* system variables include 
highest heart rate, lowest systolic blood pressure and vasopressor use. The aetiology of ARDS^ was coded as Trauma, 
Sepsis, Aspiration, Pneumonia or Other. Abbreviations: P/F = PaO2/FiO2 ratio; ANG1/2 = Angiopoietin 1 and 2; tPA = Tissue 
plasminogen activator; PAI-1 = plasminogen activator inhibitor-1; GM-CSF = granulocyte-monocyte colony stimulating factor; 
ICAM-1 = intracellular adhesion molecule-1; IFN-γ = Interferon-gamma; IL-1β = interleukin-1 beta; Interleukins = IL-6; IL-8; IL-
10; IL-13; TNF-α = Tumor necrosis factor-alpha; MMP-8 = matrix metalloproteinase-8; TIMP-1= tissue inhibitor of 
metalloproteinase-1; SP-D = Surfactant protein-D; vWF = von-Williebrand’s Factor; sTNFR-1 = soluble Tumor necrosis factor 
receptor-1; BMI = body mass index; WBC = white blood cell count;   
 Several important questions remain unanswered. First, assuming the 
hyperinflammatory/reactive sub-phenotype represents a common sub-phenotype, further work is 
needed to identify the key discriminant makers to reliably define this ARDS subset. Ideally a minimal 
data-set of variables could be identified to efficiently achieve this. Second, although it remains 
unknown if ARDS sub-phenotypes respond differently to pharmacotherapies, an important aspect of 
in developing pharmacotherapies targeted at the hyperinflammatory/reactive sub-phenotype will be to 
determine the stability of the ARDS subgroup over time. This is important to determine the therapeutic 
window to intervene with a therapy targeted at this sub-phenotype. In addition, it would be important 
to define if and how moving from this sub-phenotype to an uninflamed phenotype represents 
therapeutic success or failure to guide ongoing treatment. Third, development of point-of-care assays 
along with algorithms to define these ARDS sub-phenoytpes at the bedside in real-time is essential to 
enable this information to inform clinical trials targeting these sub-phenotypes.  
 In summary, ARDS continues to be a clinical and research challenge in terms of 
developing pharmacological therapies. Bos et al provide intriguing data that highlights the need for 
further work to identify ARDS subsets with defined treatable traits. These sub-phenotypes should be 
based on modifiable biological characteristics linked to both the risk of poor outcomes and response 
to the tested treatment. This will enable personalised care of patients with ARDS. 
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